Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.

ABSTRACT:

Objectives

Randomized controlled trials of dornase alpha have shown forced expiratory volume in 1 sec (FEV(1) ) to improve in patients with cystic fibrosis (CF) but have not assessed change in the rate of lung function decline. We assessed the relationship of dornase alpha use and FEV(1) decline using the Epidemiologic Study of Cystic Fibrosis (ESCF).

Methodology

Patients aged 8-38 years who had been enrolled in ESCF for 2 years when initially treated with dornase alpha were selected if they remained on treatment during the following 2 years. A comparator group included patients aged 8-38 who were not yet reported to have received dornase alpha. For each patient we estimated the annual rate of decline in FEV(1) % predicted before and after the index using a mixed-effects mod

SUBMITTER: Konstan MW 

PROVIDER: S-EPMC4109161 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature